Journal article
Approval delays in multi-country COVID-19 trials: the case of COPCOV and the risk of therapeutic inertia
- Abstract:
-
Background: Many multi-country COVID-19 clinical trials, including those for widely available repurposed drugs with strong safety profiles, were conceptualised quickly but were unable to influence clinical treatment guidelines. The Chloroquine/Hydroxychloroquine for the Prevention of COVID-19 (COPCOV) trial, a large multi-country clinical trial sponsored by the University of Oxford, sought to determine the efficacy of hydroxychloroquine and chloroquine as a prophylaxis for COVID-19 but faced ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.6MB, Terms of use)
-
- Publisher copy:
- 10.1186/s13063-025-09300-z
Authors
- Publisher:
- BioMed Central
- Journal:
- Trials More from this journal
- Volume:
- 27
- Issue:
- 1
- Article number:
- 58
- Publication date:
- 2025-12-16
- Acceptance date:
- 2025-11-12
- DOI:
- EISSN:
-
1745-6215
- ISSN:
-
1745-6215
- Language:
-
English
- Keywords:
- Pubs id:
-
2354376
- UUID:
-
uuid_ca78eb87-0997-4c97-9fdf-35d6989b5ecb
- Local pid:
-
pubs:2354376
- Source identifiers:
-
3681213
- Deposit date:
-
2026-01-21
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record